🇺🇸 FDA
Patent

US 10519186

Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus

granted A61KA61K31/7076A61K31/708

Quick answer

US patent 10519186 (Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus) held by Atea Pharmaceuticals, Inc. expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Atea Pharmaceuticals, Inc.
Grant date
Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
52
CPC classes
A61K, A61K31/7076, A61K31/708, A61K45/06, A61K9/20